Meeting
2022 ASCO Annual Meeting
Molecular reflex testing in non-small cell lung cancer: An optimal approach?
Authors
Kari Hooper
AmeriPath, Oklahoma City, OK
Kari Hooper , Toni Witten , Benjamin Leader , Yuri Anthony Fesko , Mark Kruzel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3127)
DOI
10.1200/JCO.2022.40.16_suppl.3127
Abstract #
3127
Poster Bd #
119
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Updated molecular analysis of MET exon 14 skipping mutations (METex14) in non-small cell lung cancer (NSCLC).
First Author: Jennifer Aline Marks
Poster
2022 ASCO Annual Meeting
Implementation of a precision medicine thoracic (PREDICT) service using reflex testing in a large academic-community practice network.
First Author: Debora S. Bruno
Poster
2022 ASCO Annual Meeting
Molecular characterization of NF1-mutated NSCLC and clinical outcomes.
First Author: Christopher Gates
Poster
2021 ASCO Quality Care Symposium
Biomarker testing patterns in patients with stage IV non-small cell lung cancer (NSCLC) in U.S. community-based oncology practice setting.
First Author: Anthony Sireci